Alexandra Hughes-Wilson - May 22, 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
May 22, 2024
Transactions value $
-$383,131
Form type
4
Date filed
5/23/2024, 09:54 PM
Previous filing
Jan 26, 2024
Next filing
Jun 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $131K +93.3K +1220.04% $1.40 101K May 22, 2024 Direct F1, F2
transaction MREO American Depositary Shares representing Ordinary Shares Sale -$151K -50.4K -46.2% $2.99 58.6K May 22, 2024 Direct F1, F2, F3
transaction MREO American Depositary Shares representing Ordinary Shares Tax liability -$60.2K -43K -84.89% $1.40 7.65K May 22, 2024 Direct F1, F2
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $75.8K +75K +980.39% $1.01 82.7K May 22, 2024 Direct F1, F2
transaction MREO American Depositary Shares representing Ordinary Shares Sale -$147K -50.1K -60.6% $2.94 32.6K May 22, 2024 Direct F1, F2, F3
transaction MREO American Depositary Shares representing Ordinary Shares Tax liability -$25.2K -24.9K -76.51% $1.01 7.65K May 22, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Options Exercise -$131K -93.3K -100% $1.40 0 May 22, 2024 American Depositary Shares 93.3K $1.40 Direct F1, F2, F4
transaction MREO Share Options (Right to buy) Options Exercise -$75.8K -75K -100% $1.01 0 May 22, 2024 American Depositary Shares 75K $1.01 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $2.88 to $3.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges
F4 160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.
F5 240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.

Remarks:

Chief Patient Access and Commercial Planning